Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus (NDV) as a biological agent with potential to break therapy resistance. This avian virus combines, upon inoculati...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-08-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/7/3/66 |
| _version_ | 1818158912409436160 |
|---|---|
| author | Volker Schirrmacher Stefaan van Gool Wilfried Stuecker |
| author_facet | Volker Schirrmacher Stefaan van Gool Wilfried Stuecker |
| author_sort | Volker Schirrmacher |
| collection | DOAJ |
| description | Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus (NDV) as a biological agent with potential to break therapy resistance. This avian virus combines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic effects with 11 described immune stimulatory properties. Fifty years of clinical application of NDV give witness to the high safety profile of this biological agent. In 2015, an important milestone was achieved, namely the successful production of NDV according to Good Manufacturing Practice (GMP). Based on this, IOZK in Cologne, Germany, obtained a GMP certificate for the production of a dendritic cell vaccine loaded with tumor antigens from a lysate of patient-derived tumor cells together with immunological danger signals from NDV for intracutaneous application. This update includes single case reports and retrospective analyses from patients treated at IOZK. The review also presents future perspectives, including the concept of in situ vaccination and the combination of NDV or other oncolytic viruses with checkpoint inhibitors. |
| first_indexed | 2024-12-11T15:37:37Z |
| format | Article |
| id | doaj.art-34f33b47a3494f688e8fc9c5f9016c3e |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-12-11T15:37:37Z |
| publishDate | 2019-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-34f33b47a3494f688e8fc9c5f9016c3e2022-12-22T00:59:53ZengMDPI AGBiomedicines2227-90592019-08-01736610.3390/biomedicines7030066biomedicines7030066Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer TherapyVolker Schirrmacher0Stefaan van Gool1Wilfried Stuecker2Immune-Oncological Center Cologne (IOZK), D-50674 Cologne, GermanyImmune-Oncological Center Cologne (IOZK), D-50674 Cologne, GermanyImmune-Oncological Center Cologne (IOZK), D-50674 Cologne, GermanyResistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus (NDV) as a biological agent with potential to break therapy resistance. This avian virus combines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic effects with 11 described immune stimulatory properties. Fifty years of clinical application of NDV give witness to the high safety profile of this biological agent. In 2015, an important milestone was achieved, namely the successful production of NDV according to Good Manufacturing Practice (GMP). Based on this, IOZK in Cologne, Germany, obtained a GMP certificate for the production of a dendritic cell vaccine loaded with tumor antigens from a lysate of patient-derived tumor cells together with immunological danger signals from NDV for intracutaneous application. This update includes single case reports and retrospective analyses from patients treated at IOZK. The review also presents future perspectives, including the concept of in situ vaccination and the combination of NDV or other oncolytic viruses with checkpoint inhibitors.https://www.mdpi.com/2227-9059/7/3/66NDVviral oncolysisimmunogenic cell deathtype I interferondendritic cellsactive-specific immunotherapybispecific antibodiesgene therapycheckpoint inhibitionT cell costimulationRIG-IIFNAR |
| spellingShingle | Volker Schirrmacher Stefaan van Gool Wilfried Stuecker Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy Biomedicines NDV viral oncolysis immunogenic cell death type I interferon dendritic cells active-specific immunotherapy bispecific antibodies gene therapy checkpoint inhibition T cell costimulation RIG-I IFNAR |
| title | Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy |
| title_full | Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy |
| title_fullStr | Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy |
| title_full_unstemmed | Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy |
| title_short | Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy |
| title_sort | breaking therapy resistance an update on oncolytic newcastle disease virus for improvements of cancer therapy |
| topic | NDV viral oncolysis immunogenic cell death type I interferon dendritic cells active-specific immunotherapy bispecific antibodies gene therapy checkpoint inhibition T cell costimulation RIG-I IFNAR |
| url | https://www.mdpi.com/2227-9059/7/3/66 |
| work_keys_str_mv | AT volkerschirrmacher breakingtherapyresistanceanupdateononcolyticnewcastlediseasevirusforimprovementsofcancertherapy AT stefaanvangool breakingtherapyresistanceanupdateononcolyticnewcastlediseasevirusforimprovementsofcancertherapy AT wilfriedstuecker breakingtherapyresistanceanupdateononcolyticnewcastlediseasevirusforimprovementsofcancertherapy |